Latest Publications

Share:

HHS Kicks Off Rare Disease Week with FDA Release of Draft Guidance on Plausible Mechanism Framework for Individualized Therapies

On February 23, 2026, the Food and Drug Administration (FDA) released a draft guidance entitled “Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic...more

Congress Rallies to Extend Rare Pediatric Disease Priority Review Voucher Program

On February 3, 2026, the Consolidated Appropriations Act, 2026 (P.L. 119-75) became law and marked an important milestone in the bipartisan congressional effort to reauthorize the rare pediatric disease priority review...more

Food Update | GRAS‑ping the Moment: FDA GRAS Reform Steps Into the Spotlight

In case you missed it, Department of Health and Human Services Secretary Robert F. Kennedy Jr. and former Food and Drug Administration (FDA) Commissioner David Kessler appeared on 60 Minutes this past Saturday, February 15,...more

A New Recipe for GRAS? FDA’s Proposed Mandatory GRAS Notification Rule, BHA RFI and Congressional Reform Bills

It is no exaggeration to say that the past year has seen the most significant push to reform the U.S. Food and Drug Administration’s (FDA) generally recognized as safe (GRAS) process in more than two decades (see our prior...more

FDA PreCheck Pilot Program Launches, Clearing a Smooth Path to Approval

On February 1, 2026, the Food and Drug Administration (FDA) officially started accepting requests to participate in the FDA PreCheck pilot program. The goal of the program is to strengthen the domestic pharmaceutical supply...more

Self‑Collection Kits in the Crosshairs

The Food and Drug Administration (FDA) has begun 2026 with a clear signal to the direct‑to‑consumer testing industry: self‑collection devices remain firmly within the agency’s regulatory reach, notwithstanding the 2025 court...more

Digesting the New Dietary Guidelines with Key Takeaways for Regulated Entities

On January 7, 2026, the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Agriculture (USDA) released the highly anticipated 2025-2030 Dietary Guidelines for Americans (DGA). At roughly 10 pages,...more

FDA Issues Key Guidance Updates for Digital Health and Wellness

On January 6, the Food and Drug Administration (FDA) updated its guidance documents on Clinical Decision Support (CDS) software and general wellness products, and withdrew its guidance on the adoption of international...more

FDA Releases Final Guidance on Best Practices for Bioresearch Monitoring Inspections

On December 18, 2025, the Food and Drug Administration (FDA) released a final guidance entitled “Processes and Practices Applicable to Bioresearch Monitoring Inspections.” The guidance was issued to comply with the Food and...more

BIOSECURE Act Becomes Law

On December 18, the BIOSECURE Act became law as Sec. 851 of the National Defense Authorization Act (NDAA) for Fiscal Year 2026. The BIOSECURE Act will prohibit the U.S. government from contracting with any company that uses...more

FDA’s TEMPO Pilot Seeks to Expand Access to Chronic Disease Technologies in CMS Collaboration

On December 5, 2025, FDA announced its Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot, a new voluntary pilot that seeks to accelerate innovation and expand access to digital health...more

Artificial Intelligence in Clinical Decision-Making: Regulatory Roadmap and Reimbursement Strategies

Artificial intelligence is rapidly transforming clinical medicine, with AI-powered tools increasingly being used for diagnostic imaging interpretation, clinical decision support, predictive analytics and treatment planning....more

An Overview of the Over-the-Counter Monograph Drug User Fee Amendments (OMUFA): Policy Areas to Watch

On November 12, 2025, President Trump signed H.R. 5371, the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026, into law (P.L. 119-37). In addition...more

FDA Issues Draft Guidance with Updated Recommendations for Assessing the Need for Comparative Efficacy Studies in Biosimilar...

Last week, FDA released draft guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies.” This draft...more

Akin Intelligence Newsletter - August/September 2025

On October 21, 2025, the Commerce Department’s International Trade Administration (ITA) announced the launch of the American AI Exports Program following President Trump’s July 23 executive order (EO) on Promoting the Export...more

FDA Presses Forward on Patient-Focused Drug Development, Releases Final Guidance Focused on Fit-For-Purpose Clinical Outcome...

On October 23, 2025, FDA released its final guidance regarding Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments. The guidance is the third guidance in a...more

FDA Continues Focus on AI Fronts, Seeks Public Comment on Measuring and Evaluating AI-enabled Medical Device Performance in the...

On September 30, 2025, the Food and Drug Administration (FDA) published a Request for Public Comment to obtain feedback from interested parties on current approaches to measuring and evaluating the performance of AI-enabled...more

FDA’s Latest on Emergency Diagnostics and a No-Frills Rescission of the LDT Rule

On Tuesday, September 23, 2025, FDA published guidance titled “Consideration of Enforcement Policies for In Vitro Diagnostic Tests During a Section 564 Declared Emergency.” The guidance, a draft of which was published on May...more

FDA Puts Orange B on the Chopping Block

Last week, the U.S. Food and Drug Administration (FDA) issued a proposed rule to revoke the color additive listing for Orange B, a synthetic dye historically used on the casings and surfaces of frankfurters and sausages. This...more

From Foods to Pharmaceuticals, MAHA Strategy Offers Broad Menu of FDA Actions

The White House’s Make America Healthy Again (MAHA) Commission, led by the Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., released its highly anticipated strategy outlining a multi-agency...more

FDA Continues Focus on Rare Disease Drug Development, Announces Evidence Principles

On September 3, 2025, the Food and Drug Administration (FDA) announced Rare Disease Evidence Principles (RDEP) with processes aimed at providing greater predictability and facilitating the development and review of drugs...more

Congress Joins FDA in Focusing on Food Dye Limitations

Food dye reform has been an area of focus for the Trump administration as part of its Make America Healthy Again (MAHA) initiative, giving momentum to an effort the Food and Drug Administration (FDA) had already started by...more

OMUFA Reauthorization On Deck as Congress Returns from Recess

In March 2020, Congress enacted the first Over-the-Counter (OTC) Monograph Drug User Fee program (OMUFA) as part of the CARES Act (P.L. 116 – 136) to modernize the Food and Drug Administration’s regulation of OTC monograph...more

Akin Intelligence - July 2025

White House Releases America’s AI Action Plan On July 23, 2025, the White House released America’s AI Action Plan. The plan, initiated by President Donald J. Trump's Executive Order 14179, "Removing Barriers to American...more

Citizen Petition Calls on FDA to Rethink Refined Carbs

Last week, former Food and Drug Administration (FDA) Commissioner David Kessler submitted a citizen petition urging FDA to revoke the generally recognized as safe (GRAS) status of refined carbohydrates used in industrial food...more

148 Results
 / 
View per page
Page: of 6

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide